Day One Biopharmaceuticals (DAWN) Equity Ratio: 2022-2025
Historic Equity Ratio for Day One Biopharmaceuticals (DAWN) over the last 4 years, with Sep 2025 value amounting to 0.88.
- Day One Biopharmaceuticals' Equity Ratio fell 5.08% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 5.08%. This contributed to the annual value of 0.86 for FY2024, which is 6.39% down from last year.
- Latest data reveals that Day One Biopharmaceuticals reported Equity Ratio of 0.88 as of Q3 2025, which was down 1.16% from 0.89 recorded in Q2 2025.
- In the past 5 years, Day One Biopharmaceuticals' Equity Ratio ranged from a high of 0.97 in Q1 2022 and a low of 0.77 during Q2 2024.
- For the 3-year period, Day One Biopharmaceuticals' Equity Ratio averaged around 0.90, with its median value being 0.91 (2024).
- Its Equity Ratio has fluctuated over the past 5 years, first fell by 18.96% in 2024, then grew by 15.91% in 2025.
- Day One Biopharmaceuticals' Equity Ratio (Quarterly) stood at 0.95 in 2022, then fell by 3.12% to 0.92 in 2023, then declined by 6.39% to 0.86 in 2024, then dropped by 5.08% to 0.88 in 2025.
- Its Equity Ratio was 0.88 in Q3 2025, compared to 0.89 in Q2 2025 and 0.90 in Q1 2025.